{
    "@context": {
        "schema": "https://schema.org/",
        "dct": "http://purl.org/dc/terms/",
        "hg": "https://hormuz.group/data/ns#"
    },
    "id": "hg:company:temad-company",
    "identifier": "hg:company:temad-company",
    "dataset_type": "entity_dataset",
    "entity_type": "company",
    "data_version": "2.0",
    "generated_by": "Hormuz Data Layer 0.2.1",
    "generated_at": "2026-07-04T02:51:17+00:00",
    "name": "Temad Company",
    "slug": "temad-company",
    "status": "publish",
    "url": "https://hormuz.group/companies/temad-company/",
    "json_url": "https://hormuz.group/wp-content/uploads/hormuz-data/cpt/company/temad-company.json",
    "rest_url": "https://hormuz.group/wp-json/hormuz-data/v1/cpt/company/temad-company",
    "summary": "",
    "machine_summary": "Temad Company Temad Company is a listed pharmaceutical raw-material producer and one of Iran's most strategically important API manufacturers. In the Hormuz Group company graph, it matters because API production sits upstream of finished medicine supply, import substitution, controlled-substance regulation, pharmaceutical exports, and the resilience of domestic drug manufacturers. Its TPICO/SHASTA affiliation and listed status make it a key node for monitoring Iran's pharmaceutical raw-material base. Temad is relevant for investors assessing Iran's API localization, listed pharmaceutical exposure, controlled-substance manufacturing, export-oriented pharmaceutical raw materials, and dependence of downstream drug producers on domestic inputs. It can support analysis of medicine-supply resilience, margin sensitivity to regulated pricing, export sales, raw-material import exposure, and technology capability in complex chemical synthesis. Due diligence should review updated Codal disclosures, ordinary-share trading status, product registrations, narcotic and non-narcotic API licenses, GMP certifications, export markets, TPICO ownership, regulatory controls, environmental compliance, supplier dependencies, and sanctions or controlled-substance compliance risk. Temad Company manufactures active pharmaceutical ingredients, narcotic and non-narcotic APIs, semi-finished pharmaceutical materials, pellets, direct-compression grades, finished dosage forms, synthetic narcotics, controlled pharmaceutical raw materials, veterinary APIs, and knowledge-based pharmaceutical products. It operates as an API producer within the TPICO and SHASTA-linked pharmaceutical ecosystem. province: Tehran industry: Chemicals, Healthcare & Pharma, Pharmaceuticals market: Enterprise Demand, Healthcare, Materials, Supply Chains challenges: Compliance, Import Dependence, Supply Shortage, Technology Gap company_type: Manufacturer city: Tehran",
    "published_at": "2026-06-28T20:35:59+00:00",
    "modified_at": "2026-06-28T20:35:59+00:00",
    "taxonomies": {
        "province": [
            {
                "id": 3,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/provinces/tehran/"
            }
        ],
        "industry": [
            {
                "id": 95,
                "name": "Chemicals",
                "slug": "chemicals",
                "url": "https://hormuz.group/industry/manufacturing/chemicals/"
            },
            {
                "id": 21,
                "name": "Healthcare & Pharma",
                "slug": "healthcare-pharma",
                "url": "https://hormuz.group/industry/healthcare-pharma/"
            },
            {
                "id": 121,
                "name": "Pharmaceuticals",
                "slug": "pharmaceuticals",
                "url": "https://hormuz.group/industry/healthcare-pharma/pharmaceuticals/"
            }
        ],
        "market": [
            {
                "id": 40,
                "name": "Enterprise Demand",
                "slug": "enterprise-demand",
                "url": "https://hormuz.group/market/enterprise-demand/"
            },
            {
                "id": 69,
                "name": "Healthcare",
                "slug": "healthcare",
                "url": "https://hormuz.group/market/consumer-demand/healthcare/"
            },
            {
                "id": 73,
                "name": "Materials",
                "slug": "materials",
                "url": "https://hormuz.group/market/enterprise-demand/materials/"
            },
            {
                "id": 76,
                "name": "Supply Chains",
                "slug": "supply-chains",
                "url": "https://hormuz.group/market/enterprise-demand/supply-chains/"
            }
        ],
        "challenges": [
            {
                "id": 164,
                "name": "Compliance",
                "slug": "compliance",
                "url": "https://hormuz.group/challenges/regulatory-barriers/compliance/"
            },
            {
                "id": 176,
                "name": "Import Dependence",
                "slug": "import-dependence",
                "url": "https://hormuz.group/challenges/market-gaps/import-dependence/"
            },
            {
                "id": 177,
                "name": "Supply Shortage",
                "slug": "supply-shortage",
                "url": "https://hormuz.group/challenges/market-gaps/supply-shortage/"
            },
            {
                "id": 179,
                "name": "Technology Gap",
                "slug": "technology-gap",
                "url": "https://hormuz.group/challenges/market-gaps/technology-gap/"
            }
        ],
        "company_type": [
            {
                "id": 299,
                "name": "Manufacturer",
                "slug": "manufacturer",
                "url": "https://hormuz.group/company-type/manufacturer/"
            }
        ],
        "city": [
            {
                "id": 384,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/cities/tehran/"
            }
        ]
    },
    "taxonomy_labels": {
        "province": "Tehran",
        "industry": "Chemicals, Healthcare & Pharma, Pharmaceuticals",
        "market": "Enterprise Demand, Healthcare, Materials, Supply Chains",
        "challenges": "Compliance, Import Dependence, Supply Shortage, Technology Gap",
        "company_type": "Manufacturer",
        "city": "Tehran"
    },
    "fields_summary": {
        "legal_name": "Tolid Mavade Avallieh Daroupakhsh Company Public Joint Stock Company",
        "website": "https://www.temad.com",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "دتماد",
        "listing_status": "listed_tse",
        "products_services": "Temad Company manufactures active pharmaceutical ingredients, narcotic and non-narcotic APIs, semi-finished pharmaceutical materials, pellets, direct-compression grades, finished dosage forms, synthetic narcotics, controlled pharmaceutical raw materials, veterinary APIs, and knowledge-based pharmaceutical products. It operates as an API producer within the TPICO and SHASTA-linked pharmaceutical ecosystem.",
        "export_relevance": "high",
        "short_profile": "Temad Company is a listed pharmaceutical raw-material producer and one of Iran's most strategically important API manufacturers. In the Hormuz Group company graph, it matters because API production sits upstream of finished medicine supply, import substitution, controlled-substance regulation, pharmaceutical exports, and the resilience of domestic drug manufacturers. Its TPICO/SHASTA affiliation and listed status make it a key node for monitoring Iran's pharmaceutical raw-material base.",
        "investment_relevance": "Temad is relevant for investors assessing Iran's API localization, listed pharmaceutical exposure, controlled-substance manufacturing, export-oriented pharmaceutical raw materials, and dependence of downstream drug producers on domestic inputs. It can support analysis of medicine-supply resilience, margin sensitivity to regulated pricing, export sales, raw-material import exposure, and technology capability in complex chemical synthesis. Due diligence should review updated Codal disclosures, ordinary-share trading status, product registrations, narcotic and non-narcotic API licenses, GMP certifications, export markets, TPICO ownership, regulatory controls, environmental compliance, supplier dependencies, and sanctions or controlled-substance compliance risk."
    },
    "fields": {
        "rank_math_internal_links_processed": "1",
        "wp_statistics_words_count": "0",
        "legal_name": "Tolid Mavade Avallieh Daroupakhsh Company Public Joint Stock Company",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "دتماد",
        "export_relevance": "high",
        "verification_status": "basic",
        "data_confidence": "high",
        "listing_status": "listed_tse",
        "last_updated": "29/06/2026",
        "website": "https://www.temad.com",
        "products_services": "Temad Company manufactures active pharmaceutical ingredients, narcotic and non-narcotic APIs, semi-finished pharmaceutical materials, pellets, direct-compression grades, finished dosage forms, synthetic narcotics, controlled pharmaceutical raw materials, veterinary APIs, and knowledge-based pharmaceutical products. It operates as an API producer within the TPICO and SHASTA-linked pharmaceutical ecosystem.",
        "short_profile": "Temad Company is a listed pharmaceutical raw-material producer and one of Iran's most strategically important API manufacturers. In the Hormuz Group company graph, it matters because API production sits upstream of finished medicine supply, import substitution, controlled-substance regulation, pharmaceutical exports, and the resilience of domestic drug manufacturers. Its TPICO/SHASTA affiliation and listed status make it a key node for monitoring Iran's pharmaceutical raw-material base.",
        "investment_relevance": "Temad is relevant for investors assessing Iran's API localization, listed pharmaceutical exposure, controlled-substance manufacturing, export-oriented pharmaceutical raw materials, and dependence of downstream drug producers on domestic inputs. It can support analysis of medicine-supply resilience, margin sensitivity to regulated pricing, export sales, raw-material import exposure, and technology capability in complex chemical synthesis. Due diligence should review updated Codal disclosures, ordinary-share trading status, product registrations, narcotic and non-narcotic API licenses, GMP certifications, export markets, TPICO ownership, regulatory controls, environmental compliance, supplier dependencies, and sanctions or controlled-substance compliance risk.",
        "source_note": "Based on public company, official-company, API-manufacturing, TPICO/SHASTA-linked pharmaceutical information, TSE/Codal disclosure, export, and market-related information. Further verification is required before treating this profile as verified investment intelligence."
    },
    "field_profile": {
        "rank_math_internal_links_processed": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "wp_statistics_words_count": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "legal_name": {
            "type": "string",
            "present": true,
            "length": 68
        },
        "city": {
            "type": "string",
            "present": true,
            "length": 29
        },
        "ticker_symbol": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "export_relevance": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "verification_status": {
            "type": "string",
            "present": true,
            "length": 5
        },
        "data_confidence": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "listing_status": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "last_updated": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "website": {
            "type": "string",
            "present": true,
            "length": 21
        },
        "products_services": {
            "type": "string",
            "present": true,
            "length": 408
        },
        "short_profile": {
            "type": "string",
            "present": true,
            "length": 491
        },
        "investment_relevance": {
            "type": "string",
            "present": true,
            "length": 768
        },
        "source_note": {
            "type": "string",
            "present": true,
            "length": 270
        }
    },
    "sources": [
        {
            "type": "note",
            "value": "Based on public company, official-company, API-manufacturing, TPICO/SHASTA-linked pharmaceutical information, TSE/Codal disclosure, export, and market-related information. Further verification is required before treating this profile as verified investment intelligence."
        }
    ],
    "quality": {
        "required_fields": [
            "legal_name",
            "website",
            "city",
            "listing_status",
            "products_services",
            "export_relevance",
            "verification_status",
            "data_confidence",
            "short_profile",
            "investment_relevance",
            "source_note",
            "last_updated"
        ],
        "missing_required_fields": [],
        "missing_required_count": 0,
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026",
        "stale_over_180_days": false,
        "quality_score": 100
    },
    "verification": {
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026"
    }
}